Related Experiment Video
Updated: Jan 7, 2026
05:40
The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
Published on: April 28, 2022
3.4K
MyWayUp: A Digital Intervention for Alcohol Use Disorder in Patients With Alcohol-Related Liver Disease-Results From
Clara Oliveras1,2,3, Mercè Balcells-Oliveró1,2,3, Ramón Bataller4,5,6
1Health and Addictions Research Group (Grup de Recerca Emergent), Institut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
Summary
A digital health intervention significantly improved alcohol use disorder (AUD) treatment retention and reduced alcohol consumption in patients with alcohol-related liver disease (ArLD). This blended approach also led to better liver function scores, supporting digital tools for AUD management.
Area of Science:
- Hepatology
- Addiction Medicine
- Digital Health
Background:
- Alcohol-related liver disease (ArLD) is a significant public health issue requiring multidisciplinary care.
- Digital health interventions show promise for improving alcohol use disorder (AUD) treatment engagement and patient outcomes.
- This study investigated a blended intervention combining a brief intervention with a serious game (SG) for AUD patients with ArLD.
Purpose of the Study:
- To evaluate the efficacy of a blended digital intervention for patients with alcohol-related liver disease and alcohol use disorder.
- To assess the impact of the intervention on treatment retention, adherence, and clinical outcomes.
Main Methods:
- A randomized, single-blinded controlled trial was conducted with patients diagnosed with recent-onset ArLD and AUD.
- The intervention group received a brief intervention plus an SG, while the control group received standard addiction therapy.
- Primary outcomes included AUD treatment retention and adherence at six months; secondary outcomes covered liver disease progression, alcohol consumption, quality of life, and functionality.
Main Results:
- Participants receiving the blended intervention were three times more likely to remain in treatment at six months (aOR 3.24) and attended 50% more appointments.
- Moderate effect sizes (Cohen's D 0.51-0.64) were observed for treatment adherence at three and six months.
- The intervention group showed significantly lower Model for End-Stage Liver Disease Sodium (MELD-Na) scores at six months (12 vs. 16) and a greater reduction in daily alcohol consumption (11 vs. 6 SDU/day at month one).
Conclusions:
- The blended digital intervention effectively increased engagement in AUD treatment for patients with ArLD.
- This approach led to reduced alcohol consumption and improved liver function markers (MELD-Na scores).
- Digital, tailored interventions are supported as a valuable tool for managing AUD in patients with liver disease.
Keywords:
adherencealcohol use disorderalcoholic liver diseasedigital healthretention to treatmentserious gamesMore Related Videos
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
01:29Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
01:29Chronic Pancreatitis II: Collaborative Care
284
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
284
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234